The endothelial angiopoietin (ANG)–TIE growth factor receptor pathway regulates vascular permeability and pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. Drugs that target the ANG–TIE pathway are in clinical development for oncological and ophthalmological applications. The aim is to complement current vascular endothelial growth factor (VEGF)-based anti-angiogenic therapies in cancer, wet age-related macular degeneration and macular oedema. The unique function of the ANG–TIE pathway in vascular stabilization also renders this pathway an attractive target in sepsis, organ transplantation, atherosclerosis and vascular complications of diabetes. This Review covers key aspects of the function of the ANG–TIE pathway in vascular disease and describes the recent development of novel therapeutics that target this pathway.

中文翻译：

---

血管生成素-TIE途径的治疗靶向

内皮血管生成素（ANG）–TIE生长因子受体途径可调节炎症，肿瘤血管生成和转移过程中的血管通透性和病理性血管重塑。靶向ANG–TIE途径的药物正在临床开发中，用于肿瘤学和眼科应用。目的是补充目前基于血管内皮生长因子（VEGF）的抗血管生成疗法，用于治疗癌症，与年龄相关的湿性黄斑变性和黄斑水肿。ANG–TIE途径在血管稳定中的独特功能也使该途径成为糖尿病的败血症，器官移植，动脉粥样硬化和血管并发症的诱人靶标。